Royalty Pharma PLC (NASDAQ:RPRX) Given Average Rating of “Buy” by Brokerages

Royalty Pharma PLC (NASDAQ:RPRX) has received a consensus recommendation of “Buy” from the six brokerages that are covering the firm, Marketbeat Ratings reports. Six investment analysts have rated the stock with a buy rating. The average 12 month price objective among brokerages that have updated their coverage on the stock in the last year is $48.6667.

RPRX has been the subject of several research reports. Wall Street Zen cut shares of Royalty Pharma from a “strong-buy” rating to a “buy” rating in a research note on Saturday, February 14th. UBS Group raised shares of Royalty Pharma from a “neutral” rating to a “buy” rating and set a $49.00 price objective on the stock in a research report on Friday, January 30th. The Goldman Sachs Group reaffirmed a “buy” rating on shares of Royalty Pharma in a research report on Thursday, February 12th. TD Cowen reiterated a “buy” rating on shares of Royalty Pharma in a research note on Friday. Finally, Leerink Partners set a $45.00 price target on shares of Royalty Pharma in a research report on Thursday, December 11th.

Insider Buying and Selling at Royalty Pharma

In other news, EVP Marshall Urist sold 23,334 shares of the stock in a transaction that occurred on Friday, December 5th. The stock was sold at an average price of $39.15, for a total value of $913,526.10. Following the completion of the sale, the executive vice president owned 160,000 shares of the company’s stock, valued at approximately $6,264,000. This represents a 12.73% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, EVP George W. Lloyd sold 110,000 shares of the business’s stock in a transaction on Wednesday, December 3rd. The stock was sold at an average price of $39.77, for a total transaction of $4,374,700.00. Following the transaction, the executive vice president owned 110,000 shares in the company, valued at approximately $4,374,700. The trade was a 50.00% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 853,863 shares of company stock worth $34,236,880 over the last ninety days. 18.90% of the stock is currently owned by corporate insiders.

Institutional Trading of Royalty Pharma

Large investors have recently added to or reduced their stakes in the company. Compound Planning Inc. raised its holdings in shares of Royalty Pharma by 21.7% in the 4th quarter. Compound Planning Inc. now owns 10,618 shares of the biopharmaceutical company’s stock valued at $410,000 after purchasing an additional 1,896 shares during the period. Corient Private Wealth LLC grew its holdings in Royalty Pharma by 26.8% during the fourth quarter. Corient Private Wealth LLC now owns 154,922 shares of the biopharmaceutical company’s stock worth $5,986,000 after purchasing an additional 32,766 shares during the period. Mercer Global Advisors Inc. ADV grew its holdings in Royalty Pharma by 25.2% during the fourth quarter. Mercer Global Advisors Inc. ADV now owns 17,177 shares of the biopharmaceutical company’s stock worth $664,000 after purchasing an additional 3,452 shares during the period. Achmea Investment Management B.V. acquired a new position in Royalty Pharma during the fourth quarter worth approximately $1,321,000. Finally, Delta Global Management LP bought a new stake in Royalty Pharma in the fourth quarter valued at approximately $1,712,000. Institutional investors and hedge funds own 54.35% of the company’s stock.

Royalty Pharma Stock Performance

RPRX opened at $47.05 on Monday. The company has a market capitalization of $27.14 billion, a price-to-earnings ratio of 34.86 and a beta of 0.40. The business’s 50-day moving average price is $41.79 and its two-hundred day moving average price is $38.87. Royalty Pharma has a 1 year low of $29.66 and a 1 year high of $46.78. The company has a debt-to-equity ratio of 0.88, a current ratio of 2.40 and a quick ratio of 2.40.

Royalty Pharma (NASDAQ:RPRX) last posted its quarterly earnings data on Wednesday, February 11th. The biopharmaceutical company reported $1.46 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.33 by $0.13. Royalty Pharma had a return on equity of 28.21% and a net margin of 32.38%.The business had revenue of $621.99 million during the quarter, compared to the consensus estimate of $839.97 million. Equities analysts expect that Royalty Pharma will post 4.49 EPS for the current fiscal year.

Royalty Pharma Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, March 10th. Investors of record on Friday, February 20th will be given a dividend of $0.235 per share. This represents a $0.94 annualized dividend and a yield of 2.0%. This is a boost from Royalty Pharma’s previous quarterly dividend of $0.22. The ex-dividend date of this dividend is Friday, February 20th. Royalty Pharma’s payout ratio is currently 69.63%.

Royalty Pharma Company Profile

Royalty Pharma plc is a specialty finance company that acquires biopharmaceutical royalty interests and provides non-dilutive financing to drug developers and rights holders. The firm purchases future royalty streams, milestone-contingent payments and other revenue rights linked to approved and late-stage pharmaceutical and biotechnology products. By paying upfront consideration for these rights, Royalty Pharma seeks to generate long-term cash flows tied to the commercial performance of a diversified portfolio of medicines.

The company’s transaction structures include outright royalty purchases, structured financings and milestone arrangements tailored to the needs of innovator companies, academic institutions and investors.